Derma Science (fka )

[BioSpecialist]

This very low float GOLDMINE could move to over 15$ in no time .DSCI is still under Radar,the highest Volume in the history of this stock is only 120K means once investors discover this stock it will move up at the speed of light with 1.5-2 Mil shares on the float .A Partnering for Blockbuster candidate DSC127 could bring huge upfront cash payment which could be much higher than current Market Cap (see post below) .DID YOU REALISE THE FANTASTIC POTENTIAL IN DSCI ??


A lot of MAJOR news coming very soon to push this GOLDMINE to ALL TIME HIGHS .


Market Cap: 34.6 MIL$
Price: 5.28 $

Shares Out: 6.5 MIL // 3 MIL Shares held by Insiders

Short Data : Only 3154 Shares


Upcoming Milestones for 1Q 2011 (New dates below are from the Company ,I got a response yesterday from IR )
http://www.wsw.com/webcast/maxim3/dsci/2__Slide21.JPG

Phase 2 results for Blockbuster Candidate DSC127 this Week or first Week in Feb 2011

Expect FDA 510k Clearance for Medihoney gel 4Q10 = VERY SOON

Submit another 510K Application to FDA for Medihoney Hydro in Jan or early Feb 2011

PartnerShip with upfront cash payment for Potential Blockbuster DSC127 2Q 2011

**************************************************************

A MUST READ ..
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10208

KEY PRODUCT UNDER DEVELOPMENT

DSDSC127 (angiotensin analog)

Novel angiotensin analog for use in wound healing and scar reduction. Successfully completed a phase I trial in 4Q07, and presently undergoing phase II trials to assess safety and efficacy of DSC127 on healing diabetic ulcers. Results from the phase II trials are expected in 4Q10.

* "Blockbuster" potential - with applications in the following markets:

o $10 billion chronic wound market
o $8 billion scar prevention/reduction market
o $6 billion burn market
o $6 billion radiation and other wound markets
* Limited competition - Systagenix's Regranex is the only FDA-approved drug for wound healing. (Systegenix is formerly Johnson & Johnson's Chronic Wound Care division.)
o Regranex has a black box warning and has achieved sales exceeding $100M per year

*************************************************************


Derma Sciences presents a unique opportunity in the micro-cap biomed space since it has a core business focused on would care which generates revenue and operating cash flow to fund the Phase 2 clinical development for a treatment (DC127) that targets a prescription drug market that is about 5X the Company’s current market cap (based on Regranex sales of $150M). In addition, pre-clinical data suggests DC127 may offer both safety and efficacy advantages over Regranex and the licensing deal by Shire for a scar prevention treatment that included a $75M up-front payment suggests Derma Sciences has the potential to secure a licensing deal that could include an up-front cash payment in excess of its current market cap of around $30M.


**************************************************************


Watch Videos about their great Products !
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10309